In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

If you have pneumonitis with Keytruda, your doctor might prescribe corticosteroid treatment for you ... reaction can include swelling under your skin, typically in your eyelids, lips, hands ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Moderna and Merck's experimental cancer vaccine, when used in combination with Keytruda ... a treatment for non-small cell lung cancer. Melanoma is responsible for the large majority of skin ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

The KEYNOTE-689 trial assessing Keytruda (pembrolizumab) for the perioperative treatment of newly diagnosed stage 3 or 4A, resected, locally advanced head and neck squamous cell carcinoma met its ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

“These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from earlier lines of therapy to ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress ...

Padcev is indicated in Japan as monotherapy for the treatment of adult patients with radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy, and in combination ...